The Myotonic Dystrophy Foundation supports scientific investigations to enhance the quality of life of people living with myotonic dystrophy and advance research focused on finding treatments and a cure for this disease. As a part of this effort, the Foundation offers a number of funding opportunities for DM researchers. Visit this page regularly or subscribe to the DM Research News to stay current on funding opportunities from MDF and the Wyck Foundation.
Current Funding Opportunities
Request for Applications - Development of a Genome Editing Strategy for Myotonic Dystrophy Type 1
MDF released an RFA July 24, 2018 for Development of a Genome Editing Strategy for Myotonic Dystrophy Type 1. Through this Request for Applications (RFA), the Myotonic Dystrophy Foundation recognizes a need to advance genome editing technology and evaluate its potential as a candidate therapy for use in myotonic dystrophy type 1 (DM1). MDF intends to issue up to two 2-year awards of up to $250,000 total cost for projects that address the evaluation of genome editing strategies that target the DMPK gene.
The focus of this RFA is on early stage discovery and development of in vivo genome editing technologies in academic laboratories or other nonprofit research institutions, utilizing state-of-the-art knowledge. This solicitation is strategy, platform and delivery vehicle agnostic, as MDF seeks the best path forward to identify optimal tools and processes to develop a therapy for DM1. The goal is to establish a proof of concept for a therapeutic that is not incremental, but has a substantial level of effect across the multiple body systems impacted by the DM1 disease.
Successful applications must not only addreess fundamental hurdles to applying genome editing but must include strategies that specifically address the complexities or the DMPK locus, including use of appropriate DM1 models at each starge of evaluation.
Collaborations between experts in genome editing technologies and those with strong track records in myotonic dystrophy research are strongly encouraged. Applications are due November 30, 2018.
Request for Applications - MDF & Wyck Foundation Training Fellowships
The Wyck Foundation and the Myotonic Dystrophy Foundation have partnered to offer training fellowships, and are pleased to announce that the 2019 Request for Applications is now open. MDF is expanding the scientific research endeavors eligible for Ph.D. Trainee and Postdoctoral Fellowship awards to include research focused on improving treatment, care and support of the DM patient and his/her family, as well as molecular biology and basic science. Trainees working in academia, research institutes or drug development companies are eligible.
Applications are due by September 3, 2018, with a start date for successful applicants of January 2019. Applicants are encouraged to contact the MDF Chief Science Officer, Dr. Elizabeth Ackermann, with any questions about this RFA or the scientific content of their proposals. Technical issues should be directed to MDF Grants Manager Elizabeth Habeeb-Louks.
MDF Grant Awards
Click here to view a list of current and former grantees, grant projects and Fellows.
Grantwriting Training for Researchers
MDF annually hosts a grant writing training at the MDF Annual Conference. In 2016, the session was presented by Tom Cheever, PhD, Program Director at the National Institute of Arthritis and Musculoskeletal, and Skin Diseases (NIAMS). In 2017, the session was presented by MDF Chief Science Officer John Porter, PhD, former Program Director at the National Institute of Neuromuscular Disorders and Stroke (NINDS) at the U.S. National Institutes of Health (NIH). View the presentation slides from Dr. Cheever (presentation slides) and Porter (presentation slides) from those training and access best-in-class grantwriting tips.
Subscribe to MDF's research news publication, DM Research News, for updates about MDF and other funding opportunities. If you are not signed up for and receiving the DM Research News, complete this form with your name, degree, institution and current work or interest in DM care, research and/or drug development and we will enroll you in the monthly newsletter.
Email MDF's Chief Scientific Officer, Dr. Elizabeth Ackermann.
For more information on MDF grantmaking policies, click here to read the MDF Request for Proposals Award Policy manual.